EFHD1抗体;EFHD1 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of EFHD1 in mouse spleen, rat spleen tissue lysates using EFHD1 antibody.    

  
  

•  

   

     Immunofluorescence analysis of EFHD1 in mouse lung using EFHD1 antibody(3G2)(red),and DAPI (blue).    

  
  

•  

   

     Immunofluorescence analysis of EFHD1 in Hela using EFHD1 antibody(Left) and DAPI (Right).    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human uterus tissue using EFHD1 antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.Negative control was used by secondary antibody only.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human tonsils using EFHD1 antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.Negative control was used by secondary antibody only.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded mouse testis tissue using EFHD1 antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval. Negative control was used by secondary antibody only.    

  
  

The EFHD1 (EF-hand domain-containing protein 1) antibody is a tool used to study the EFHD1 protein, a calcium-binding protein implicated in diverse cellular processes. EFHD1 contains two EF-hand motifs, enabling calcium-dependent interactions, and is expressed in tissues like the brain, immune cells, and testes. It regulates apoptosis, cytoskeletal dynamics, and cell migration, with roles in immune response modulation, neuronal development, and cancer progression. Dysregulation of EFHD1 has been linked to neurodegenerative diseases (e.g., Alzheimer’s) and malignancies, where it may influence tumor invasiveness or drug resistance.

EFHD1 antibodies, typically raised in rabbits or mice, are used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect EFHD1 expression, localization, and post-translational modifications. Their specificity is often validated via knockout controls or siRNA-mediated silencing. Commercial antibodies are widely employed in research exploring EFHD1's functional mechanisms, including its interplay with signaling pathways like Wnt or MAPK. Challenges include ensuring antibody specificity due to potential cross-reactivity with homologous proteins (e.g., EFHD2). Ongoing studies aim to clarify EFHD1's role as a biomarker or therapeutic target in diseases, leveraging these antibodies for translational applications.